These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
534 related articles for article (PubMed ID: 20819019)
21. TRAIL signalling: decisions between life and death. Falschlehner C; Emmerich CH; Gerlach B; Walczak H Int J Biochem Cell Biol; 2007; 39(7-8):1462-75. PubMed ID: 17403612 [TBL] [Abstract][Full Text] [Related]
22. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Zhang Y; Zhang B Mol Cancer Res; 2008 Dec; 6(12):1861-71. PubMed ID: 19074831 [TBL] [Abstract][Full Text] [Related]
23. Targeting TRAIL agonistic receptors for cancer therapy. Carlo-Stella C; Lavazza C; Locatelli A; Viganò L; Gianni AM; Gianni L Clin Cancer Res; 2007 Apr; 13(8):2313-7. PubMed ID: 17438088 [TBL] [Abstract][Full Text] [Related]
24. [Recent advances for research on anti-tumor effects of TNF-related apoptosis-inducing ligand]. Yao GH; Hou YY Wei Sheng Yan Jiu; 2006 Jan; 35(1):115-7. PubMed ID: 16598953 [TBL] [Abstract][Full Text] [Related]
25. TRAIL death receptors and cancer therapeutics. Huang Y; Sheikh MS Toxicol Appl Pharmacol; 2007 Nov; 224(3):284-9. PubMed ID: 17240413 [TBL] [Abstract][Full Text] [Related]
26. Translating TRAIL-receptor targeting agents to the clinic. den Hollander MW; Gietema JA; de Jong S; Walenkamp AM; Reyners AK; Oldenhuis CN; de Vries EG Cancer Lett; 2013 May; 332(2):194-201. PubMed ID: 22531313 [TBL] [Abstract][Full Text] [Related]
27. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Georgakis GV; Li Y; Humphreys R; Andreeff M; O'Brien S; Younes M; Carbone A; Albert V; Younes A Br J Haematol; 2005 Aug; 130(4):501-10. PubMed ID: 16098063 [TBL] [Abstract][Full Text] [Related]
28. From biochemical principles of apoptosis induction by TRAIL to application in tumour therapy. Cordier SM; Papenfuss K; Walczak H Results Probl Cell Differ; 2009; 49():115-43. PubMed ID: 19142621 [TBL] [Abstract][Full Text] [Related]
29. TNF-related apoptosis-inducing ligand cooperates with NSAIDs via activated Wnt signalling in (pre)malignant colon cells. Heijink DM; Jalving M; Oosterhuis D; Sloots IA; Koster R; Hollema H; Kleibeuker JH; Koornstra JJ; de Vries EG; de Jong S J Pathol; 2011 Feb; 223(3):378-89. PubMed ID: 21171083 [TBL] [Abstract][Full Text] [Related]
31. TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8. Belyanskaya LL; Ziogas A; Hopkins-Donaldson S; Kurtz S; Simon HU; Stahel R; Zangemeister-Wittke U Lung Cancer; 2008 Jun; 60(3):355-65. PubMed ID: 18093694 [TBL] [Abstract][Full Text] [Related]
32. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. Kim YH; Jung EM; Lee TJ; Kim SH; Choi YH; Park JW; Park JW; Choi KS; Kwon TK Free Radic Biol Med; 2008 Mar; 44(6):1055-68. PubMed ID: 18164688 [TBL] [Abstract][Full Text] [Related]
33. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells. Chen S; Liu X; Yue P; Schönthal AH; Khuri FR; Sun SY Mol Pharmacol; 2007 Nov; 72(5):1269-79. PubMed ID: 17684158 [TBL] [Abstract][Full Text] [Related]
34. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. MacFarlane M; Kohlhaas SL; Sutcliffe MJ; Dyer MJ; Cohen GM Cancer Res; 2005 Dec; 65(24):11265-70. PubMed ID: 16357130 [TBL] [Abstract][Full Text] [Related]
35. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis. Maduro JH; de Vries EG; Meersma GJ; Hougardy BM; van der Zee AG; de Jong S Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):543-52. PubMed ID: 18793956 [TBL] [Abstract][Full Text] [Related]
36. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells. Sung ES; Kim A; Park JS; Chung J; Kwon MH; Kim YS Apoptosis; 2010 Oct; 15(10):1256-69. PubMed ID: 20582477 [TBL] [Abstract][Full Text] [Related]
37. The roadmap of TRAIL apoptotic pathway-targeted cancer therapies: What is next? Bellail AC; Hao C Expert Rev Anticancer Ther; 2012 May; 12(5):547-9. PubMed ID: 22594889 [No Abstract] [Full Text] [Related]
38. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Marini P; Denzinger S; Schiller D; Kauder S; Welz S; Humphreys R; Daniel PT; Jendrossek V; Budach W; Belka C Oncogene; 2006 Aug; 25(37):5145-54. PubMed ID: 16636678 [TBL] [Abstract][Full Text] [Related]
39. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells. Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632 [TBL] [Abstract][Full Text] [Related]
40. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Motoki K; Mori E; Matsumoto A; Thomas M; Tomura T; Humphreys R; Albert V; Muto M; Yoshida H; Aoki M; Tamada T; Kuroki R; Yoshida H; Ishida I; Ware CF; Kataoka S Clin Cancer Res; 2005 Apr; 11(8):3126-35. PubMed ID: 15837769 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]